Aptose Biosciences (TSE:APS) Share Price Crosses Above 50-Day Moving Average – Should You Sell?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s share price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of C$2.19 and traded as high as C$2.33. Aptose Biosciences shares last traded at C$2.26, with a volume of 3,275 shares traded.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners cut shares of Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. One analyst has rated the stock with a Hold rating, According to MarketBeat, the company presently has an average rating of “Hold”.

Aptose Biosciences Stock Down 0.4%

The company has a market cap of C$5.77 million, a price-to-earnings ratio of 3.28 and a beta of -0.46. The business has a fifty day moving average of C$2.19 and a two-hundred day moving average of C$1.94. The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last posted its quarterly earnings data on Thursday, November 13th. The biotechnology company reported C($2.01) EPS for the quarter. As a group, equities analysts anticipate that Aptose Biosciences Inc. will post -0.59 EPS for the current fiscal year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.